These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2001455)

  • 1. Vanillin, a potential agent for the treatment of sickle cell anemia.
    Abraham DJ; Mehanna AS; Wireko FC; Whitney J; Thomas RP; Orringer EP
    Blood; 1991 Mar; 77(6):1334-41. PubMed ID: 2001455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
    Abdulmalik O; Ghatge MS; Musayev FN; Parikh A; Chen Q; Yang J; Nnamani I; Danso-Danquah R; Eseonu DN; Asakura T; Abraham DJ; Venitz J; Safo MK
    Acta Crystallogr D Biol Crystallogr; 2011 Nov; 67(Pt 11):920-8. PubMed ID: 22101818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
    Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
    Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
    Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
    Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
    Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
    Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
    Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E; Safo MK; Abdulmalik O; Kato GJ
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
    J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
    Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
    Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
    Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conductance of red blood cells from sickle cell patients: ion selectivity and inhibitors.
    Ma YL; Rees DC; Gibson JS; Ellory JC
    J Physiol; 2012 May; 590(9):2095-105. PubMed ID: 22411011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of o-vanillin on K⁺ transport of red blood cells from patients with sickle cell disease.
    Hannemann A; Cytlak UM; Gbotosho OT; Rees DC; Tewari S; Gibson JS
    Blood Cells Mol Dis; 2014; 53(1-2):21-6. PubMed ID: 24594314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
    Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-sickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents.
    Zhang C; Li X; Lian L; Chen Q; Abdulmalik O; Vassilev V; Lai CS; Asakura T
    Br J Haematol; 2004 Jun; 125(6):788-95. PubMed ID: 15180869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action.
    Suhail M
    Sci Rep; 2024 Jan; 14(1):1861. PubMed ID: 38253605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.